Mirikizumab in Crohn's disease

Milikizumab (Mirikizumab) is a humanized monoclonal antibody targeting the IL-23p19 subunit. It is mainly used for the treatment of moderately to severely active inflammatory bowel disease, includingulcerative colitis and Crohn's disease. IL-23 is a key pro-inflammatory factor in inflammatory bowel disease. It triggers intestinal mucosal inflammation and tissue damage by activating Th17 cells and producing a variety of pro-inflammatory cytokines. By specifically inhibiting the IL-23 signaling pathway, Militizumab can reduce the secretion of inflammatory mediators, thereby controlling chronic intestinal inflammation and abnormal immune responses, and providing patients with a targeted and efficient treatment option.

Clinical studies have shown that militizumab is effective in Crohn's disease. In a study of 1,152 patients with moderately to severely active Crohn's disease, militizumab was effective in improving disease symptoms when conventional treatments were ineffective or had unacceptable side effects. In the study, about 38% of patients who received militizumab experienced improvement in intestinal symptoms at 12 weeks, and by 52 weeks, intestinal inflammation markers dropped significantly. In comparison, only about 9% of patients in the placebo group showed improvement in symptoms after 12 weeks. In addition, approximately 45% of patients on militizumab experienced significant relief of overall symptoms after 12 weeks and a significant reduction in overall disease severity by 52 weeks, whereas only approximately 20% of patients in the placebo group achieved similar improvements. These data suggest that militizumab can provide a reliable treatment pathway for patients who are refractory to or poorly tolerated by conventional therapies.

The advantage of Militizumab lies not only in inflammation control, but also in its precise immunomodulatory mechanism targetingIL-23, which can reduce the risk of systemic immunosuppression, thus showing good safety in long-term maintenance treatment. For complex cases, including patients with recurrence after surgery, recurrent intestinal inflammation or associated complications, militizumab provides a new management strategy to help reduce the risk of disease progression and improve quality of life.

Reference materials:https://omvoh.lilly.com/